Biosimilar and biologics

Biosimilars the Generic form of organic is the new popular expression in pharmaceutical industry. Biosimilars are exceptionally like authorized reference item not withstanding minor contrasts in clinically idle parts; additionally there are no clinically significant contrasts between the organic and the reference item as far as wellbeing, virtue, and strength. This track incorporates: Licensing of Biosimilars, Biomarkers direction, Patent issues, BLA petitioning for Biosimilars, Regulatory prospects of BRIC nations, a worldview of customary generics to Biosimilars, Biologics& Bio waiver endorsement for Biosimilars and different parts of Biosimilar endorsements.

  • Bio-analytics for Biosimilars
  • Extrapolation and Interchangeability
  • Legal Considerations for Biosimilars
  • Biosimilar Uptake and Market Considerations
  • Challenges and regulatory approach for biosimilars
  • Future of next generation biosimilars

Related Conference of Biosimilar and biologics

June 06-07, 2018

International Conference & B2B on Pharma Research and Development

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Biosimilar and biologics Conference Speakers

Recommended Sessions

Related Journals

Are you interested in